Moves follow disagreement with Danish drugmaker’s majority shareholder the Novo Nordisk Foundation

Moves follow disagreement with Danish drugmaker’s majority shareholder the Novo Nordisk Foundation

Novo Nordisk directors and the firm's controlling shareholder failed to reach an agreement on the future composition of the board.

Boardroom shake-up at European drugmaker grants Lars Rebien Sørensen wide-ranging powers